Kinase News and Research

RSS

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced.

24 Feb 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

A research team led by investigators from Mayo Clinic's campus in Jacksonville, Florida, and the University of Oslo, Norway, have identified a molecule that pushes normal pancreatic cells to transform their shape, laying the groundwork for development of pancreatic cancer -- one of the most difficult tumors to treat.

21 Feb 2015

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

This is the story of Abl and Src -- two nearly identical protein kinases whose evolution may hold the key to unlocking new, highly specific cancer drugs.

20 Feb 2015

UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.

18 Feb 2015

TKI introduction improves French CML patient survival

Real-world study findings from France show the significant impact tyrosine kinase inhibitor treatment has had on the survival of patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Rare and classic EGFR mutations have different impacts on NSCLC outcome

Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common "classical" EGFR mutations.

12 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint.

11 Feb 2015

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.

10 Feb 2015

Discovery improves understanding of factors that trigger allergic asthma

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies.

9 Feb 2015

New study provides better understanding of how stem cells give rise to tumors

Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a precise stem cell signaling process that can lead to intestinal tumors if disrupted. The findings add to our understanding of how stem cells give rise to tumors and identify specific stem cell molecules that may be targeted to prevent the onset, progression, and recurrence of intestinal cancers.

6 Feb 2015

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain.

5 Feb 2015

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

A new molecule has been found that protects the heart from toxic breast cancer drugs and also kills the cancerous tumour. The research from Italy addresses the burgeoning problem of heart disease in cancer survivors and is announced by the European Society of Cardiology today on World Cancer Day.

4 Feb 2015

Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

31 Jan 2015

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

The U.S. Food and Drug Administration approval of ibrutinib (Imbruvica) to treat patients with Waldenstrom's macroglobulinemia(WM) is a significant advance for patients with this rare blood cancer.

31 Jan 2015

Kinase News and Research

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

TKI introduction improves French CML patient survival

Transplantation conditioning choices impact on CML outcomes revealed

Second-line bosutinib well tolerated by Japanese patients

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Rare and classic EGFR mutations have different impacts on NSCLC outcome

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Discovery improves understanding of factors that trigger allergic asthma

New study provides better understanding of how stem cells give rise to tumors

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Research: New molecule safeguards heart from toxic breast cancer drugs, kills cancerous tumour

Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News